Abstract

Borderline ovarian tumors (BOT) represent about 10 to 20 percent of all epithelial tumors of the ovary. They constitute intermediate lesions between benign ovarian cysts and invasive carcinomas. They often occur in young women of reproductive age, and, albeit with a favorable prognosis, it may recur on the ipsilateral or contralateral ovary. Controversies surround the diagnostic criteria used for their assessment, and the optimal management to minimize their risk of recurrence and/or transformation into malignant carcinoma. Fertility preservation (FP) is considered a priority in the management of these patients, and studies aim at finding the safest and most effective way to help women with BOT history conceive with minimal risk. We present the experience of a single institution in managing three cases of serous BOT in young nulliparous women, followed by a thorough review of the existing literature, highlighting controversies and exploring the possible FP techniques for these women.

Highlights

  • Borderline ovarian tumors (BOT) behave as intermediate lesions between benign cystadenomas and invasive carcinomas, making them a separate histologic and clinical entity

  • Fertility preservation (FP) has become a major part of the management of these patients [4]. These tumors are often diagnosed at an early stage while still confined to one or both ovaries, considered as stage I BOT according to the International Federation of Gynecology and Obstetrics (FIGO)

  • Borderline ovarian tumours represent a unique clinical entity characterized by a favourable prognosis when diagnosed and managed in a timely manner

Read more

Summary

Introduction

Borderline ovarian tumors (BOT) behave as intermediate lesions between benign cystadenomas and invasive carcinomas, making them a separate histologic and clinical entity. They represent 10 to 20 percent of all epithelial tumors of the ovary. Fertility preservation (FP) has become a major part of the management of these patients [4]. These tumors are often diagnosed at an early stage while still confined to one or both ovaries, considered as stage I BOT according to the International Federation of Gynecology and Obstetrics (FIGO)

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call